0001567619-21-017166.txt : 20210915
0001567619-21-017166.hdr.sgml : 20210915
20210915183558
ACCESSION NUMBER: 0001567619-21-017166
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210913
FILED AS OF DATE: 20210915
DATE AS OF CHANGE: 20210915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yednock Ted
CENTRAL INDEX KEY: 0001818525
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39402
FILM NUMBER: 211256439
MAIL ADDRESS:
STREET 1: C/O ANNEXON, INC.
STREET 2: 180 KIMBALL WAY, SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annexon, Inc.
CENTRAL INDEX KEY: 0001528115
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 275414423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 KIMBALL WAY
STREET 2: SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650)-822-5500
MAIL ADDRESS:
STREET 1: 180 KIMBALL WAY
STREET 2: SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2021-09-13
0
0001528115
Annexon, Inc.
ANNX
0001818525
Yednock Ted
C/O ANNEXON, INC.
180 KIMBALL WAY, SUITE 200
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
EVP & Chief Scientific Officer
Common Stock
2021-09-13
4
M
0
15000
1.4096
A
15000
D
Common Stock
2021-09-13
4
M
0
1190
5.1098
A
16190
D
Common Stock
2021-09-13
4
S
0
16190
20.0037
D
0
D
Stock Option (Right to Buy)
1.4096
2021-09-13
4
M
0
15000
0.00
D
2025-01-22
Common Stock
15000
10615
D
Stock Option (Right to Buy)
5.1098
2021-09-13
4
M
0
1190
0.00
D
2029-01-22
Common Stock
1190
67939
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades in prices ranging from $20.00 to $20.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares subject to the option vest are fully vested and exercisable.
1/48th of the shares subject to the option vest on each monthly anniversary measured from December 12, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Jennifer Lew, as Attorney-in-Fact for Ted Yednock
2021-09-15